论文部分内容阅读
目的探讨重组免疫印迹试验（ＲＩＢＡ）在急性丙型肝炎中的应用价值及ＨＣＶ不同编码区抗体在急性丙型肝炎诊断中的意义。方法本文建立了含ＨＣＶ不同编码区３种重组抗原（Ｃ２２，Ｃ３３Ｃ，Ｃ１００＿３）的ＲＩＢＡ，对２０例急性输血后丙肝患者血清相应抗体进行了动态监测并与第二代放免法（ＲＩＡ＿２）检测抗＿ＨＣＶ结果进行比较。结果病程１月及３月内ＲＩＢＡ阳性率均显著高于ＲＩＡ＿２的阳性率（８５％ｖｓ４０％，Ｐ＜００５；１００％ｖｓ７０％，Ｐ＜００５）。急性丙肝血清中抗＿Ｃ２２及抗＿Ｃ３３ｃ早期检出率（病程１月内分别为９０％和８０％，３个月时均为１００％）显著高于抗＿Ｃ１００＿３（１月内为４５％，３个月时为７０％）。结论ＨＣＶ核心区抗体（抗＿Ｃ２２）及ＮＳ３区抗体（抗＿Ｃ３３ｃ）在急性丙肝中出现早，检出率高，具有早期诊断价值，ＲＩＢＡ可提高急性ＨＣＶ感染的早期诊断率。
Objective To investigate the value of recombinant immunoblot assay (RIBA) in the diagnosis of acute hepatitis C and its significance in the diagnosis of acute hepatitis C (HCV). Methods RIBA containing three recombinant antigens (C22, C33C and C100_3) in different coding regions of HCV was established in this study. Serum corresponding antibodies in 20 hepatitis C patients after acute transfusion were dynamically monitored and compared with the second generation RIA_2 _HCV results for comparison. Results The positive rates of RIBA in the first month and the third month were significantly higher than those of RIA_2 (85% vs 40%, P <005; 100% vs 70%, P <005). The early detection rate of anti-C22 and anti-C33c in acute hepatitis C was significantly higher than that in anti-C100_3 (45% in 3 months and 90% in 1 month and 80% in 3 months, respectively) Month, 70%). Conclusion The detection rate of HCV core antibody (anti-C22) and NS3 antibody (anti-C33c) in early diagnosis of acute hepatitis C is high and early detection rate. RIBA can improve the early diagnosis rate of acute HCV infection.